Replimune said the agency had issued a complete response letter regarding the company’s biologics license application for RP1 ...

Replimune (REPL) stock plummeted on Tuesday after the biotechnology company received a Complete Response Letter (CRL) from ...

Replimune (REPL) stock rebounds even as FDA rejection of its RP1 skin cancer drug lead to multiple analyst downgrades on Wall Street. Read more here.

SAN FRANCISCO, July 23, 2025 (GLOBE NEWSWIRE) -- Investors in Replimune Group, a biotechnology company focused on cancer treatments, witnessed a dramatic collapse in their holdings on July 22. Shares ...

Replimune stock fell after the FDA rejected its RP1 application, citing flaws in the trial design and lack of substantial evidence for approval.

Replimune, however, said the combination therapy showed that the rate of complete disappearance of tumors, also known as the complete response rate (CRR), was "just short" of statistical significance.

Replimune Group Inc. (REPL) reported its first-quarter earnings for 2025, revealing a significant miss on expected earnings per share (EPS) and a subsequent drop in stock price. The company posted ...

Why Replimune Stock Is Soaring Today. ... Shares of Replimune Group (REPL 1.71%) were soaring 13.3% higher as of 11:01 a.m. EDT on Thursday after rising as much as 22.4% earlier in the day.

In addition, in lieu of common stock to certain investors, Replimune today announced the pricing of its public offering of pre-funded warrants to purchase 3,846,184 shares of its. BOSTON, ...